Kidney Transplantation Alone in End-Stage Renal Disease Patients with Hepatitis B Liver Cirrhosis
1Division of Nephrology, Department of Internal Medicine, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Republic of Korea
2Division of Nephrology, Department of Internal Medicine, Choengju St. Mary's General Hospital, Choengjusi, Republic of Korea.
Meeting: 2018 American Transplant Congress
Abstract number: C181
Keywords: Hepatitis B, Kidney transplantation, Liver cirrhosis
Session Information
Session Name: Poster Session C: Kidney Technical
Session Type: Poster Session
Date: Monday, June 4, 2018
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall 4EF
Background
Kidney transplantation (KT) alone in end-stage renal disease (ESRD) patients with hepatitis B virus-induced liver cirrhosis (LC) remains controversial. This study compared outcomes of KT in hepatitis B surface antigen (HBsAg)-positive patients with ESRD with LC (LC group) and without LC (non-LC group).
Methods
Outcomes were analyzed in 116 HBsAg-positive patients with ESRD who underwent KT alone between 1997 and 2013 and who were followed for at least 1 year. Ninety-nine were in the non-LC group and 17 were in the LC group; of the latter, 12 were Child Pugh (CP) class A and five were CP class B.
Results
Baseline aspartate transaminase (AST) and alanine transaminase (ALT) levels were higher in the LC group. Model for end-stage liver disease (MELD) scores were similar in patients that were CP class A and B; only serum albumin level was lower in CP class B. After KT, one CP class A patient showed increases in CP score (from 5 to 10 points) and in MELD score (from 22.3 to 44.1 points). The CP and MELD scores of the other 16 patients in the LC group did not increase. All five pre-KT CP class B patients were reclassified as class A after KT because of elevated serum albumin levels. Four patients in the LC group developed hepatocellular carcinoma a median of 35 months (range, 20–57 months) after KT. The 5-year patient survival rate was similar in the LC and non-LC groups. The occurrence of hepatocellular carcinoma was significantly higher inpatients who died than in survivors.
Conclusions
KT alone may be safe in patients with compensated hepatitis B virus-induced LC.
CITATION INFORMATION: Jang M., Lee M., Kim S. Kidney Transplantation Alone in End-Stage Renal Disease Patients with Hepatitis B Liver Cirrhosis Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Jang M, Lee M, Kim S. Kidney Transplantation Alone in End-Stage Renal Disease Patients with Hepatitis B Liver Cirrhosis [abstract]. https://atcmeetingabstracts.com/abstract/kidney-transplantation-alone-in-end-stage-renal-disease-patients-with-hepatitis-b-liver-cirrhosis/. Accessed November 21, 2024.« Back to 2018 American Transplant Congress